Navigation Links
Regulatory immune cell diversity tempers autoimmunity in rheumatoid arthritis
Date:5/8/2012

Untangling the root cause of rheumatoid arthritis has been a difficult task for immunologists, as decades of research has pointed to multiple culprits in our immune system, with contradictory lines of evidence. Now, researchers at The Wistar Institute announce that it takes a diverse array of regulatory T cells (a specialized subset of white blood cells) to prevent the immune system from generating the tissue-specific inflammation that is a hallmark of the disease. Regulatory T cell diversity, the researchers say, provides a cumulative protective effect against rheumatoid arthritis. When that diversity is not present, it allows the immune system to attack joints.

The Wistar scientists presented their findings, developed in a mouse model of rheumatoid arthritis, in the May 1 issue of the Journal of Immunology. Defining the immune mechanisms involved in rheumatoid arthritis could point to new therapies for the disease.

"Our results show, surprisingly, that suppressing the immune response against a single target will not shut down the inflammatory response that causes rheumatoid arthritis," said Andrew J. Caton, Ph.D., senior author and professor in The Wistar Institute Cancer Center's Tumor Microenvironment and Metastasis program. "Instead, an array of inflammation-stimulating antigens may be involved in causing the disease, since our study shows that an array of regulatory T cells is required to temper the immune system's attack on joints."

Rheumatoid arthritis (RA) is an autoimmune disorder that occurs as the immune system attacks the synovium, the membrane that lines all the joints of the body. It is a common disorder that causes uncontrolled inflammationresulting in pain and swellingaround the joints. It is thought that approximately one percent of the adult population, worldwide, suffers from rheumatoid arthritis. RA has shown to be exacerbated by drinking and smoking, and the disease can lead to an overall increased risk of death.

While the exact cause of RA is unknown, the Caton laboratory and others have shown that a variety of white blood cells called regulatory T cells (or Tregs) are a necessary component to either restrain (or encourage) the immune system's inflammatory response. Tregs are activated as molecules on their surface membranes called T cell receptors interact with "friendly" or "self" moleculesa way for the immune system to recognize friend from foe. Mismanagement of these Tregs, which normally serve to restrain the immune system from over-reacting to healthy tissue, could then lead to runaway inflammation.

In this study, the researchers sought to examine how T cell receptors affect the ability of Tregs to suppress arthritis in a mouse that had been bred to express a "self" molecule that drives arthritis. They showed that an array of Tregs given to the mice effectively stops arthritis. Unexpectedly, however, Tregs that are specific for the surrogate "self" molecule do not prevent arthritis.

"We find that the Treg responsible for recognition of the disease-initiating self antigen are sufficient for stopping arthritis, but a diverse repertoire of Tregs are very effective," Caton said. "All of these Tregs, together, influence other components of the immune system which serves to slow down the inflammatory process that causes RA."

According to Caton, their findings also point to a possible answer of why the immune system targets the membranes that line joints. Tregs influence other types of T cells to produce a substance known as IL-17, and these cells often travel through the body's lymphatic system where they then drain out into the joints.

"The big unanswered question of RA is 'why are joints targeted?'" Caton said. "Of all the tissues in the body, of all the places our immune system could attack, this question remains."

"One idea is that the immune system isn't deliberately attacking joints in patients with rheumatoid arthritis," Caton said, "but the joint inflammation is a side effect of the natural tendency of these cells to accumulate in these areas of the body."


'/>"/>

Contact: Greg Lester
glester@wistar.org
215-898-3943
The Wistar Institute
Source:Eurekalert

Related medicine news :

1. Regulatory enzyme overexpression may protect against neurodegeneration in Huntingtons disease
2. Moffitt Cancer Center researchers find regulatory T-cell clue to help prevent GVHD
3. FDA awards Georgetown University a Center of Excellence in Regulatory Science & Innovation
4. Key regulatory genes often amplified in aggressive childhood tumor of the brainstem
5. FDA should invest in developing a new regulatory framework to replace flawed 510(k) medical device clearance process
6. Specialized regulatory T cell stifles antibody production centers
7. Newly discovered regulatory mechanism essential for embryo development and may contribute to cancer
8. “Global Supply Chain Visibility and Security; Business Necessity, Regulatory Imperative”
9. RAPS Seeks Nominations for Regulatory Awards, RAPS Fellows
10. iSirona Appoints Chief Quality and Regulatory Officer to Oversee Quality Initiatives
11. NIH-FDA Joint Briefing on Regulatory Science Collaboration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2017)... ... September 20, 2017 , ... ... specializing in medical device compliance and commercialization, has just released a new ... , FDA is more adamant than ever about medical device, pharmaceutical, and ...
(Date:9/20/2017)... ... September 20, 2017 , ... As part of The Garland ... a redesigned website. The new site – still located at http://www.garlandco.com ... and other industry users that Garland serves. , After an ambitious phase of ...
(Date:9/20/2017)... (PRWEB) , ... September 20, 2017 , ... ... digital and social campaign, “Humans With Vaginas.” The goal is to ignite conversation ... of non-toxic personal care products. The brand has declared September “Humans with Vaginas” ...
(Date:9/20/2017)... ... 20, 2017 , ... Health & Safety Institute (HSI) is offering discounted pricing ... 40-Hour courses from now until November 30, 2017 to assist with the clean-up efforts ... to all businesses and government agencies – whether or not they will be directly ...
(Date:9/20/2017)... ... September 20, 2017 , ... “Finn Mouseson”: follows the exciting story of ... life. This mouse sets out on a journey that will show that friends are ... creation of newly published author and illustrator, Melody Gersonde-Mickelson, who has earned a bachelor’s ...
Breaking Medicine News(10 mins):
(Date:9/12/2017)... 12, 2017  ValGenesis Inc., the global leader ... pleased to announce the appointment of Dr. ... Board of Directors and Chairman of Advisory Board ... science companies to manage their entire validation lifecycle ... in this process. Furthermore, ValGenesis VLMS enables rigorous ...
(Date:9/9/2017)... -- Eli Lilly and Company (NYSE: LLY ) ... lasmiditan, an investigational, oral, first-in-class molecule for the acute ... to placebo in the Phase 3 SPARTAN study. Detailed ... of the International Headache Society (IHC) in ... demonstrate lasmiditan,s potential to reduce pain and provide freedom ...
(Date:9/7/2017)... , Sept. 7, 2017 Caris Life ... on fulfilling the promise of precision medicine, today ... the benefits of its molecular profiling approach in ... comprehensive genomic profiling plus (CGP+) with Caris Molecular ... tumor on a molecular level, leading to more ...
Breaking Medicine Technology: